

REMARKS


This amendment is submitted in an earnest effort to bring this case to issue without delay.

Applicants have canceled claims 91 through 94, 96 through 99, 101 through 104, 106 and 109 through 118. Applicants have amended claims 95, 100 and 105 and added new claims 119 through 121. Antecedent basis for the amendments to claims 95, 100 and 105 and for new claims 119 through 121 may be found in the substitute specification on pages 15 through 22 in Examples 3 through 6 where the strains of *C. Glutamicum* transformed with the vector of the present invention are disclosed. Thus claims 95, 100, 105, 107, 108 and 119 through 121 are now in the application and are presented for examination.

Applicants appreciate the Examiner's indication that claims 107 and 108 are allowable over the cited prior art, namely PETERS-WENDISCH et al, DILLON et al, GUBLER et al, and MEADOW et al. Now that Applicants have amended claims 96, 100, and 105 to be limited to the bacterium *Corynebacterium* transformed with a vector containing the isolated polynucleotide of SEQ ID NO:1, and have drafted new claims 119 through 121 to be directed to a method of microbial production of L-threonine or L-serine using the transformed *Corynebacterium* with a vector containing the isolated polynucleotide of SEQ ID NO:1 according to the present invention, it is believed that these claims should be allowable as well.

Favorable action is earnestly solicited.

Respectfully submitted,
The Firm of Karl F. Ross P.C.


Jonathan Myers, Reg. No. 26,963
Attorney for Applicant

er

November 27, 2006
5676 Riverdale Avenue Box 900
Bronx, NY 10471-0900
Cust. No.: 535
Tel: (718) 884-6600
Fax: (718) 601-1099